» Articles » PMID: 15952993

Osteopenia and Osteoporosis: Previously Unrecognized Manifestations of Fabry Disease

Overview
Journal Clin Genet
Specialty Genetics
Date 2005 Jun 15
PMID 15952993
Citations 21
Authors
Affiliations
Soon will be listed here.
Citing Articles

Decreased trabecular bone score in patients affected by Fabry disease.

Varaldo E, Giannone B, Viglino F, Settanni F, Bioletto F, Barale M J Endocrinol Invest. 2024; 48(1):121-130.

PMID: 39361238 PMC: 11729064. DOI: 10.1007/s40618-024-02427-x.


The Effect of Fabry Disease Therapy on Bone Mineral Density.

Aitken T, Tiong M, Talbot A, Ruderman I, Nicholls K Diseases. 2024; 12(5).

PMID: 38785757 PMC: 11120203. DOI: 10.3390/diseases12050102.


Increased Soluble Interleukin 6 Receptors in Fabry Disease.

Lenzini L, Iori E, Vettore M, Gugelmo G, Radu C, Padoan A J Clin Med. 2024; 13(1).

PMID: 38202225 PMC: 10780051. DOI: 10.3390/jcm13010218.


Reduced hip bone mineral density is associated with high levels of calciprotein particles in patients with Fabry disease.

Bruell S, Nicholls K, Hewitson T, Talbot A, Holt S, Smith E Osteoporos Int. 2022; 33(8):1783-1794.

PMID: 35575807 PMC: 9499881. DOI: 10.1007/s00198-022-06420-z.


Serum neurofilament light chain is not a useful biomarker of central nervous system involvement in women with Fabry disease.

Holub T, Kedzierska K, Muras-Szwedziak K, Nowicki M Intractable Rare Dis Res. 2021; 10(4):276-282.

PMID: 34877240 PMC: 8630462. DOI: 10.5582/irdr.2021.01115.